Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Dev Dyn. 2016 Sep 18;245(11):1097–1106. doi: 10.1002/dvdy.24439

Figure 5.

Figure 5

Grhl2 is significantly decreased in vivo and in vitro after treatment with DAPT during postnatal pituitary development. Schematic representing dosing paradigm for mice treated with DAPT, a gamma secretase inhibitor that is known to block Notch signaling (A). A significant decrease is observed in Grhl2 mRNA levels after in vivo treatment with DAPT (B). Schematic showing paradigm for pituitary explant culture treatment with DAPT (C). A significant decrease is observed in Grhl2 mRNA levels after in vitro DAPT treatment compared to vehicle treated controls. Grhl2 mRNA levels recover after DAPT is removed from the culture media (D). *, P < 0.05. n= 5 to 8 (qRT-PCR in vivo), and n= 4 to 8 (qRT-PCR in vitro).